Point of care platelet activity measurement in Primary Percutaneous Coronary Intervention (PPCI)

A study of Platelet INhibition using a 'POINT of care' platelet function test, following Primary Percutaneous Coronary Intervention for ST elevation myocardial infarction (PINPOINT-PPCI)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN82257414

Enrollment

108

Registered

2012-06-07

Start date

2011-03-17

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST elevation myocardial infarction Circulatory System Acute myocardial infarction

Interventions

Platelet function (measured in peripheral 'whole' blood) will be assessed on arrival at hospital, at completion of the PPCI, 1, 2 and 24 hours after the completion of the PPCI. These measurements will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A participant may enter the study if ALL of the following apply: 1. Admitted with acute ST elevation myocardial infarction (STEMI) 2. Treated with PPCI at the time of index procedure

Exclusion criteria

Exclusion criteria: A participant may not enter the study if ANY of the following apply: 1. Unable to take prasugrel 2. Unable to take bivalirudin 3. Haemodynamic instability/cardiogenic shock 4. Current treatment with clopidogrel or prasugrel

Design outcomes

Primary

Measure	Time frame
1. The platelet function assessment measured in peripheral whole blood 2. Functional assessment of Adenosine diphosphate (ADP) receptor, arachidonic acid pathway, and thrombin related platelet activation will be measured using a multiple electrode analyser (MEA - Multiplate platelet function analysis) Platelet function (measured in peripheral 'whole' blood, see above) will be assessed on arrival at hospital, at completion of the PPCI, 1, 2 and 24 hours after the completion of the PPCI. These measurements will allow the study to test how the profile of platelet function changes over the period of time in which the effect of bivalirudin wanes and prasugrel increases, by assessing the interaction between door-to-balloon time and time-after-completion of PPCI.	—

Measure

Time frame

1. The platelet function assessment measured in peripheral whole blood 2. Functional assessment of Adenosine diphosphate (ADP) receptor, arachidonic acid pathway, and thrombin related platelet activation will be measured using a multiple electrode analyser (MEA - Multiplate platelet function analysis) Platelet function (measured in peripheral 'whole' blood, see above) will be assessed on arrival at hospital, at completion of the PPCI, 1, 2 and 24 hours after the completion of the PPCI. These measurements will allow the study to test how the profile of platelet function changes over the period of time in which the effect of bivalirudin wanes and prasugrel increases, by assessing the interaction between door-to-balloon time and time-after-completion of PPCI.

—

Secondary

Measure	Time frame
Incidence of adverse clinical events at 24hours and 30days, including: 1. Major adverse cardiac events (MACE) - a composite of target vessel revascularisation, target lesion revascularisation, non-fatal myocardial infarction, and cardiac death 2. Bleeding complications - using Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding criteria 3. Stent thrombosis [Academic Research Consortium (ARC) definition]	—

Measure

Time frame

Incidence of adverse clinical events at 24hours and 30days, including: 1. Major adverse cardiac events (MACE) - a composite of target vessel revascularisation, target lesion revascularisation, non-fatal myocardial infarction, and cardiac death 2. Bleeding complications - using Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding criteria 3. Stent thrombosis [Academic Research Consortium (ARC) definition]

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026